Daniel Soffer

PRG DIR & CLIN PROF

JX-MEDICINE AT JAX

  • PRG DIR & CLIN PROF
    JX-MEDICINE AT JAX

GRANTS

  • GRANT
    MagicTouch - Sirolimus-Coated Balloon for treatment of Coronary Artery Lesions in Small Vessels
    Concept Medical23 Dec 2025 - 22 Dec 2030
    Active
  • GRANT
    Magical RCT CTA
    Concept Medical14 Aug 2024 - 13 Aug 2029
    Active
  • GRANT
    A Prospective Randomized Single-Blind Multicenter Study to Assess the Safety and Efficacy of the SELUTION SLR™ 014 PTCA Drug Eluting Balloon in in the Treatment of Subjects with De Novo Coronary Lesions in Small Vessels
    Med Alliance28 Jun 2024 - 27 Jun 2029
    Active
  • GRANT
    Efficacy of the COronary SInus Reducer in Patients with Refractory Angina II (COSIRA-II)
    Shockwave Medical17 Feb 2024 - 17 Feb 2029
    Active
  • GRANT
    MedAlliance Selution ISR IDE
    Med Alliance13 Jul 2023 - 13 Jul 2028
    Active
  • GRANT
    Allay Study
    Alleviant Medical18 Apr 2023 - 29 Dec 2024
    Closed
  • GRANT
    The Protect IV Trial
    Abiomed8 Jul 2022 - 8 Jul 2027
    Active
  • GRANT
    “{“CGUARD – An Investigation of a Neuroprotective Stent A Multicenter, Single-Arm, Pivotal Study to Evaluate the Safety and Efficacy of the CGuard™ Carotid Stent System When Used to Treat Symptomatic and Asymptomatic Carotid Artery Stenosis in Patients Undergoing Carotid Artery Stenting. (“C-Guardians”PROTOCOL TITLE}” in accordance with Sponsor’s protocol number PRO-9017
    Inspire Md4 May 2022 - 3 May 2027
    Active
  • GRANT
    Long-Term Observational Extension of Participants in the CREST-2 Randomized Clinical Trial
    National Institute of Health Ninds1 Sep 2021 - 31 Aug 2026
    Active
  • GRANT
    CAROTID REVASCULARIZATION AND MEDICAL MANAGEMENT FOR ASYMPTOMATIC CAROTID STENOSIS TRIAL (CREST-2) PROTOCOL
    National Institute of Health Ninds22 Dec 2020 - 31 Aug 2025
    Expired
  • GRANT
    Global multicenter, open-label, randomized, event-driven, activecontrolled study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement (TAVR) to Optimize clinical outcomes.
    Bayer Healthcare Pharmaceuticals14 Jul 2016 - 12 Apr 2022
    Closed
  • GRANT
    AN INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBOCONTROLLED PHASE 3 TRIAL INVESTIGATING THE EFFICACY AND ....
    Bayer Healthcare Pharmaceuticals26 Jan 2016 - 30 Mar 2021
    Closed